AIDS. 2025 Oct 27. doi: 10.1097/QAD.0000000000004380. Online ahead of print.
ABSTRACT
BACKGROUND: Immune checkpoint inhibitor (ICI) therapy has demonstrated safety and efficacy in a variety of malignancies, including cancers affecting patients with human immunodeficiency virus (PWH). However, there is limited data directly comparing efficacy of ICI use between cancer patients with versus without HIV.
METHODS: Real-world retrospective data were used to compare clinical outcomes between 24 PWH and cancer 24 matched cancer patients without HIV, all treated with ICI therapy.
RESULTS: Adverse event rates did not differ by HIV status. Overall response (complete or partial response) to ICI therapy was observed in 29% of PWH compared to 38% of people without HIV (PWoH), but this difference was not statistically significant. The overall survival at end of study follow-up by HIV status was similar between both groups (63% in PWH and 67% in PWoH).
CONCLUSIONS: These findings suggest that HIV status alone should not preclude use of ICI therapy to improve prognosis among PWH and cancer.
PMID:41143744 | DOI:10.1097/QAD.0000000000004380
